Adimab Obtains Series F Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1c6cd9d9-e631-451f-b2ac-58f111ff0279&Preview=1 - Date
4/2/2012 - Company Name
Adimab - Mailing Address
16 Cavendish Court Lebanon, NH 03766 - Company Description
Adimab–which stands for Antibody Discovery Maturation Biomanufacturing–is developing a platform that’s deliberately engineered to minimize and potentially eliminate third party royalties, offering a one-stop-service-shop to a select few Big Pharma partners. - Website
http://www.adimab.com - Transaction Type
Venture Equity - Transaction Amount
Undisclosed - Transaction Round
Series F - Proceeds Purposes
We are accelerating the expansion of our platform to include additional applications such as the development of bi-specific antibodies, antibody-drug conjugates, targeting cell based antigens including GPCRs and ion channels, as well as preclinical manufacturing and mammalian cell line development. - M&A Terms
- Venture Investor
Undisclosed
